ABIT:XETRA:XETRA-AXA IM ACT Biodiversity Equity UCITS ETF - USD Acc EUR (EUR)

ETF | Others |

Last Closing

USD 11.588

Change

-0.02 (-0.17)%

Market Cap

N/A

Volume

79.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-02 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

-0.77 (-1.72%)

USD 96.80B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.09 (-0.09%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

-0.28 (-1.22%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

-0.13 (-0.98%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

-0.05 (-0.97%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

-0.09 (-0.41%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

+0.01 (+0.09%)

USD 23.43B
PPFB:XETRA iShares Physical Gold ETC EUR

-0.24 (-0.43%)

USD 19.49B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

+0.06 (+0.60%)

USD 12.83B
EUN5:XETRA iShares Core Corporate Bond UC..

-0.10 (-0.08%)

USD 12.26B

ETFs Containing ABIT:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.08% 26% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.08% 28% F 28% F
Trailing 12 Months  
Capital Gain 0.21% 27% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.21% 29% F 33% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 8.73% 59% D- 59% D-
Dividend Return 8.73% 57% F 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 9.16% 65% D 72% C
Risk Adjusted Return 95.35% 81% B- 84% B
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike